Lv1
70 积分 2023-12-11 加入
Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches
5天前
已关闭
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy
8天前
已关闭
DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients
12天前
已完结
Association Between Hyperkalemia, CKD Progression, and All-Cause Mortality: The REVOLUTIONIZE II Study
12天前
已关闭
Consensus document on the management of hyperkalemia
13天前
已完结
Consensus statement on the management of hyperkalaemia—An Asia–Pacific perspective
15天前
已完结
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
1个月前
已完结
Long-term outcomes of IgA nephropathy in China
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2个月前
已完结
Foreword
3个月前
已完结
皖公网安备34019202002308
